Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5209MR)

This product GTTS-WQ5209MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5209MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15787MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ14938MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ1845MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ10276MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ9357MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ7009MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ8900MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ11018MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW